Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1987 Oct;31(10):1461–1464. doi: 10.1128/aac.31.10.1461

Alanine aminopeptidase and beta 2-microglobulin excretion in patients receiving vancomycin and gentamicin.

M J Rybak 1, J J Frankowski 1, D J Edwards 1, L M Albrecht 1
PMCID: PMC174971  PMID: 2893584

Abstract

The effects of vancomycin, gentamicin, and combination vancomycin-gentamicin treatments on alanine aminopeptidase (AAP) and beta 2-microglobulin (beta 2M) elimination in 30 hospitalized patients were assessed and compared with elimination in a control group. Twenty-four-hour urine excretion values for AAP and beta 2M were determined on treatment day 1 and day 5 for patients receiving the three treatment regimens and for the control group. AAP excretion values for the vancomycin-treated group were not found to be statistically different from those of the control group. Both the gentamicin and the vancomycin-gentamicin groups had statistically higher AAP excretion values on treatment day 1 as well as on treatment day 5 when compared with the vancomycin and control groups. AAP excretion on day 5 of treatment was highest for the vancomycin-gentamicin group. Overall, beta 2M elimination was variable in all treatment groups. Although the beta 2M values were elevated as early as day 1 in all treatment groups, they were significantly elevated only in the vancomycin-gentamicin group on day 1 and only in the gentamicin group on day 5 compared with the vancomycin and the control groups. AAP appears to be a sensitive indicator of renal tubular damage. The combination of vancomycin and gentamicin results in greater AAP excretion than does either agent alone.

Full text

PDF
1461

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aronoff G. R., Sloan R. S., Dinwiddie C. B., Jr, Glant M. D., Fineberg N. S., Luft F. C. Effects of vancomycin on renal function in rats. Antimicrob Agents Chemother. 1981 Feb;19(2):306–308. doi: 10.1128/aac.19.2.306. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Blumer J. L., Reed M. D. Clinical pharmacology of aminoglycoside antibiotics in pediatrics. Pediatr Clin North Am. 1983 Feb;30(1):195–208. doi: 10.1016/s0031-3955(16)34329-2. [DOI] [PubMed] [Google Scholar]
  3. Coppens L., Hanson B., Klastersky J. Therapy of staphylococcal infections with cefamandole or vancomycin alone or with a combination of cefamandole and tobramycin. Antimicrob Agents Chemother. 1983 Jan;23(1):36–41. doi: 10.1128/aac.23.1.36. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Diener U., Knoll E., Langer B., Rautenstrauch H., Ratge D., Wisser H. Urinary excretion of N-acetyl-beta-D-glucosaminidase and alanine aminopeptidase in patients receiving amikacin or cis-platinum. Clin Chim Acta. 1981 May 5;112(2):149–157. doi: 10.1016/0009-8981(81)90373-9. [DOI] [PubMed] [Google Scholar]
  5. Esposito A. L., Gleckman R. A. Vancomycin. A second look. JAMA. 1977 Oct 17;238(16):1756–1757. doi: 10.1001/jama.238.16.1756. [DOI] [PubMed] [Google Scholar]
  6. Farber B. F., Moellering R. C., Jr Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981. Antimicrob Agents Chemother. 1983 Jan;23(1):138–141. doi: 10.1128/aac.23.1.138. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Gibey R., Dupond J. L., Alber D., Leconte des Floris R., Henry J. C. Predictive value of urinary N-acetyl-beta-D-glucosaminidase (NAG), alanine-aminopeptidase (AAP) and beta-2-microglobulin (beta 2M) in evaluating nephrotoxicity of gentamicin. Clin Chim Acta. 1981 Oct 8;116(1):25–34. doi: 10.1016/0009-8981(81)90165-0. [DOI] [PubMed] [Google Scholar]
  8. Harwick H. J., Kalmanson G. M., Guze L. B. In vitro activity of ampicillin or vancomycin combined with gentamicin or streptomycin against enterococci. Antimicrob Agents Chemother. 1973 Oct;4(4):383–387. doi: 10.1128/aac.4.4.383. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Jung K., Scholz D. An optimized assay of alanine aminopeptidase activity in urine. Clin Chem. 1980 Aug;26(9):1251–1254. [PubMed] [Google Scholar]
  10. Katzmann J. A., Greipp P. R., O'Fallon W. M., Kyle R. A. Serum beta 2-microglobulin. Mayo Clin Proc. 1986 Sep;61(9):752–753. doi: 10.1016/s0025-6196(12)62777-3. [DOI] [PubMed] [Google Scholar]
  11. Keys T. F., Kurtz S. B., Jones J. D., Muller S. M. Renal toxicity during therapy with gentamicin or tobramycin. Mayo Clin Proc. 1981 Sep;56(9):556–559. [PubMed] [Google Scholar]
  12. Marre R., Müller W., Sack K. Animal studies on the reduction of aminoglycoside-induced nephrotoxicity by D-glucaro-1,5-lactam. Infection. 1983 May-Jun;11(3):155–160. doi: 10.1007/BF01641295. [DOI] [PubMed] [Google Scholar]
  13. Marre R., Schulz E., Anders T., Sack K. Renal tolerance and pharmacokinetics of vancomycin in rats. J Antimicrob Chemother. 1984 Sep;14(3):253–260. doi: 10.1093/jac/14.3.253. [DOI] [PubMed] [Google Scholar]
  14. Moellering R. C., Jr Pharmacokinetics of vancomycin. J Antimicrob Chemother. 1984 Dec;14 (Suppl 500):43–52. doi: 10.1093/jac/14.suppl_d.43. [DOI] [PubMed] [Google Scholar]
  15. Plesner T. Immunochemical studies of human beta 2-microglobulin. A review of recent methodological progress and clinical applications. Allergy. 1980 Dec;35(8):627–637. doi: 10.1111/j.1398-9995.1980.tb02015.x. [DOI] [PubMed] [Google Scholar]
  16. Rybak M. J., Boike S. C. Additive toxicity in patients receiving vancomycin and aminoglycosides. Clin Pharm. 1983 Nov-Dec;2(6):508–508. [PubMed] [Google Scholar]
  17. Sabath L. D. Mechanisms of resistance to beta-lactam antibiotics in strains of Staphylococcus aureus. Ann Intern Med. 1982 Sep;97(3):339–344. doi: 10.7326/0003-4819-97-3-339. [DOI] [PubMed] [Google Scholar]
  18. Saravolatz L. D., Pohlod D. J., Arking L. M. Community-acquired methicillin-resistant Staphylococcus aureus infections: a new source for nosocomial outbreaks. Ann Intern Med. 1982 Sep;97(3):325–329. doi: 10.7326/0003-4819-97-3-325. [DOI] [PubMed] [Google Scholar]
  19. Schiffman G. Immune responses to pneumococcal polysaccharide antigens: a comparison of the murine model and the response in humans. Rev Infect Dis. 1981 Mar-Apr;3(2):224–232. doi: 10.1093/clinids/3.2.224. [DOI] [PubMed] [Google Scholar]
  20. Sethi K., Diamond L. H. Aminoglycoside nephrotoxicity and its predictability. Nephron. 1981;27(4-5):265–270. doi: 10.1159/000182065. [DOI] [PubMed] [Google Scholar]
  21. Sorrell T. C., Collignon P. J. A prospective study of adverse reactions associated with vancomycin therapy. J Antimicrob Chemother. 1985 Aug;16(2):235–241. doi: 10.1093/jac/16.2.235. [DOI] [PubMed] [Google Scholar]
  22. Trollfors B., Alestig K., Krantz I., Norrby R. Quantitative nephrotoxicity of gentamicin in nontoxic doses. J Infect Dis. 1980 Mar;141(3):306–309. doi: 10.1093/infdis/141.3.306. [DOI] [PubMed] [Google Scholar]
  23. Watanakunakorn C., Tisone J. C. Synergism between vancomycin and gentamicin or tobramycin for methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains. Antimicrob Agents Chemother. 1982 Nov;22(5):903–905. doi: 10.1128/aac.22.5.903. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Wood C. A., Kohlhepp S. J., Kohnen P. W., Houghton D. C., Gilbert D. N. Vancomycin enhancement of experimental tobramycin nephrotoxicity. Antimicrob Agents Chemother. 1986 Jul;30(1):20–24. doi: 10.1128/aac.30.1.20. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES